img

Global and United States Radioimmunotherapy Market Report & Forecast 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global and United States Radioimmunotherapy Market Report & Forecast 2024-2034

Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
Market Analysis and InsightsGlobal and United States Radioimmunotherapy Market
This report focuses on global and United States Radioimmunotherapy market, also covers the segmentation data of other regions in regional level and county level.
The global Radioimmunotherapy revenue was US$ 1042.8 million in 2022 and is forecast to a readjusted size of US$ 4477.8 million by 2029 with a CAGR of 17.4% during the review period (2024-2034).
Global 5 largest Companies of Radioimmunotherapy are Novartis, Bayer, China Isotope & Radiation, Curium Pharmaceuticals and Aurobindo Pharma, which make up over 99%. Among them, Novartis is the leader with about 85% market share. North America is the largest market, with a share about 51%, followed by Europe and Asia-Pacific, with the share about 33% and 14%. In terms of product type, Beta-emitting occupy the largest share of the total market, about 85%. And in terms of product Application, the largest application is Solid Tumor, followed by Non Hodgkin Lymphoma.
Global Radioimmunotherapy Scope and Market Size
Radioimmunotherapy market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Radioimmunotherapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2029.
For United States market, this report focuses on the Radioimmunotherapy market size by players, by Type and by Application, for the period 2018-2029. The key players include the global and local players, which play important roles in United States.



By Company


Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals
Segment by Type
Beta-emitting
Targeted Alpha Therapy

Segment by Application


Solid Tumor
Non Hodgkin Lymphoma
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Radioimmunotherapy definition, global market size, United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Radioimmunotherapy companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Radioimmunotherapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Radioimmunotherapy revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions

Table of Content

1 Study Coverage
1.1 Radioimmunotherapy Product Introduction
1.2 Global Radioimmunotherapy Outlook 2018 VS 2022 VS 2029
1.2.1 Global Radioimmunotherapy Market Size for the Year 2018-2029
1.2.2 United States Radioimmunotherapy Market Size for the Year 2018-2029
1.3 Radioimmunotherapy Market Size, United States VS Global, 2018 VS 2022 VS 2029
1.3.1 The Market Share of United States Radioimmunotherapy in Global, 2018 VS 2022 VS 2029
1.3.2 The Growth Rate of Radioimmunotherapy Market Size, United States VS Global, 2018 VS 2022 VS 2029
1.4 Radioimmunotherapy Market Dynamics
1.4.1 Radioimmunotherapy Industry Trends
1.4.2 Radioimmunotherapy Market Drivers
1.4.3 Radioimmunotherapy Market Challenges
1.4.4 Radioimmunotherapy Market Restraints
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered
2 Radioimmunotherapy by Type
2.1 Radioimmunotherapy Market Segment by Type
2.1.1 Beta-emitting
2.1.2 Targeted Alpha Therapy
2.2 Global Radioimmunotherapy Market Size by Type (2018, 2022 & 2029)
2.3 Global Radioimmunotherapy Market Size by Type (2018-2029)
2.4 United States Radioimmunotherapy Market Size by Type (2018, 2022 & 2029)
2.5 United States Radioimmunotherapy Market Size by Type (2018-2029)
3 Radioimmunotherapy by Application
3.1 Radioimmunotherapy Market Segment by Application
3.1.1 Solid Tumor
3.1.2 Non Hodgkin Lymphoma
3.2 Global Radioimmunotherapy Market Size by Application (2018, 2022 & 2029)
3.3 Global Radioimmunotherapy Market Size by Application (2018-2029)
3.4 United States Radioimmunotherapy Market Size by Application (2018, 2022 & 2029)
3.5 United States Radioimmunotherapy Market Size by Application (2018-2029)
4 Global Radioimmunotherapy Competitor Landscape by Company
4.1 Global Radioimmunotherapy Market Size by Company
4.1.1 Global Key Companies of Radioimmunotherapy, Ranked by Revenue (2022)
4.1.2 Global Radioimmunotherapy Revenue by Player (2018-2024)
4.2 Global Radioimmunotherapy Concentration Ratio (CR)
4.2.1 Radioimmunotherapy Market Concentration Ratio (CR) (2018-2024)
4.2.2 Global Top 5 and Top 10 Largest Companies of Radioimmunotherapy in 2022
4.2.3 Global Radioimmunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Players of Radioimmunotherapy Head office and Area Served
4.4 Global Key Players of Radioimmunotherapy, Product and Application
4.5 Global Key Players of Radioimmunotherapy, Date of Enter into This Industry
4.6 Companies Mergers & Acquisitions, Expansion Plans
4.7 United States Radioimmunotherapy Market Size by Company
4.7.1 Key Players of Radioimmunotherapy in United States, Ranked by Revenue (2022)
4.7.2 United States Radioimmunotherapy Revenue by Players (2021, 2022 & 2024)
5 Global Radioimmunotherapy Market Size by Region
5.1 Global Radioimmunotherapy Market Size by Region: 2018 VS 2022 VS 2029
5.2 Global Radioimmunotherapy Market Size by Region (2018-2029)
5.2.1 Global Radioimmunotherapy Market Size by Region: 2018-2024
5.2.2 Global Radioimmunotherapy Market Size by Region (2024-2029)
6 Americas
6.1 Americas Radioimmunotherapy Market Size YoY Growth 2018-2029
6.2 Americas Radioimmunotherapy Market Size by Type
6.2.1 Americas Radioimmunotherapy Market Size by Type (2018-2024)
6.2.2 Americas Radioimmunotherapy Market Size by Type (2024-2029)
6.2.3 Americas Radioimmunotherapy Market Share by Type (2018-2029)
6.3 Americas Radioimmunotherapy Market Size by Application
6.3.1 Americas Radioimmunotherapy Market Size by Application (2018-2024)
6.3.2 Americas Radioimmunotherapy Market Size by Application (2024-2029)
6.3.3 Americas Radioimmunotherapy Market Share by Application (2018-2029)
6.4 Americas Radioimmunotherapy Market Facts & Figures by Country (2018, 2022 & 2029)
6.4.1 United States
6.4.2 Canada
6.4.3 Mexico
6.4.4 Brazil
7 EMEA
7.1 EMEA Radioimmunotherapy Market Size YoY Growth 2018-2029
7.2 EMEA Radioimmunotherapy Market Size by Type
7.2.1 EMEA Radioimmunotherapy Market Size by Type (2018-2024)
7.2.2 EMEA Radioimmunotherapy Market Size by Type (2024-2029)
7.2.3 EMEA Radioimmunotherapy Market Share by Type (2018-2029)
7.3 EMEA Radioimmunotherapy Market Size by Application
7.3.1 EMEA Radioimmunotherapy Market Size by Application (2018-2024)
7.3.2 EMEA Radioimmunotherapy Market Size by Application (2024-2029)
7.3.3 EMEA Radioimmunotherapy Market Share by Application (2018-2029)
7.4 EMEA Radioimmunotherapy Market Facts & Figures by Country (2018, 2022 & 2029)
7.4.1 Europe
7.4.2 Middle East
7.4.3 Africa
8 China
8.1 China Radioimmunotherapy Market Size YoY Growth 2018-2029
8.2 China Radioimmunotherapy Market Size by Type
8.2.1 China Radioimmunotherapy Market Size by Type (2018-2024)
8.2.2 China Radioimmunotherapy Market Size by Type (2024-2029)
8.2.3 China Radioimmunotherapy Market Share by Type (2018-2029)
8.3 China Radioimmunotherapy Market Size by Application
8.3.1 China Radioimmunotherapy Market Size by Application (2018-2024)
8.3.2 China Radioimmunotherapy Market Size by Application (2024-2029)
8.3.3 China Radioimmunotherapy Market Share by Application (2018-2029)
9 APAC (excluding China)
9.1 APAC Radioimmunotherapy Market Size YoY Growth 2018-2029
9.2 APAC Radioimmunotherapy Market Size by Type
9.2.1 APAC Radioimmunotherapy Market Size by Type (2018-2024)
9.2.2 APAC Radioimmunotherapy Market Size by Type (2024-2029)
9.2.3 APAC Radioimmunotherapy Market Share by Type (2018-2029)
9.3 APAC Radioimmunotherapy Market Size by Application
9.3.1 APAC Radioimmunotherapy Market Size by Application (2018-2024)
9.3.2 APAC Radioimmunotherapy Market Size by Application (2024-2029)
9.3.3 APAC Radioimmunotherapy Market Share by Application (2018-2029)
9.4 APAC Radioimmunotherapy Market Facts & Figures by Country (2018, 2022 & 2029)
9.4.1 Japan
9.4.2 South Korea
9.4.3 China Taiwan
9.4.4 Southeast Asia
9.4.5 India
10 Key Players Profiles
10.1 Bayer
10.1.1 Bayer Company Details
10.1.2 Bayer Business Overview
10.1.3 Bayer Radioimmunotherapy Introduction
10.1.4 Bayer Revenue in Radioimmunotherapy Business (2018-2024)
10.1.5 Bayer Recent Development
10.2 Novartis
10.2.1 Novartis Company Details
10.2.2 Novartis Business Overview
10.2.3 Novartis Radioimmunotherapy Introduction
10.2.4 Novartis Revenue in Radioimmunotherapy Business (2018-2024)
10.2.5 Novartis Recent Development
10.3 Lantheus
10.3.1 Lantheus Company Details
10.3.2 Lantheus Business Overview
10.3.3 Lantheus Radioimmunotherapy Introduction
10.3.4 Lantheus Revenue in Radioimmunotherapy Business (2018-2024)
10.3.5 Lantheus Recent Development
10.4 Aurobindo Pharma
10.4.1 Aurobindo Pharma Company Details
10.4.2 Aurobindo Pharma Business Overview
10.4.3 Aurobindo Pharma Radioimmunotherapy Introduction
10.4.4 Aurobindo Pharma Revenue in Radioimmunotherapy Business (2018-2024)
10.4.5 Aurobindo Pharma Recent Development
10.5 Mundipharma
10.5.1 Mundipharma Company Details
10.5.2 Mundipharma Business Overview
10.5.3 Mundipharma Radioimmunotherapy Introduction
10.5.4 Mundipharma Revenue in Radioimmunotherapy Business (2018-2024)
10.5.5 Mundipharma Recent Development
10.6 China Isotope & Radiation
10.6.1 China Isotope & Radiation Company Details
10.6.2 China Isotope & Radiation Business Overview
10.6.3 China Isotope & Radiation Radioimmunotherapy Introduction
10.6.4 China Isotope & Radiation Revenue in Radioimmunotherapy Business (2018-2024)
10.6.5 China Isotope & Radiation Recent Development
10.7 Curium Pharmaceuticals
10.7.1 Curium Pharmaceuticals Company Details
10.7.2 Curium Pharmaceuticals Business Overview
10.7.3 Curium Pharmaceuticals Radioimmunotherapy Introduction
10.7.4 Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024)
10.7.5 Curium Pharmaceuticals Recent Development
10.8 Gilead Sciences
10.8.1 Gilead Sciences Company Details
10.8.2 Gilead Sciences Business Overview
10.8.3 Gilead Sciences Radioimmunotherapy Introduction
10.8.4 Gilead Sciences Revenue in Radioimmunotherapy Business (2018-2024)
10.8.5 Gilead Sciences Recent Development
10.9 Clarity Pharmaceuticals
10.9.1 Clarity Pharmaceuticals Company Details
10.9.2 Clarity Pharmaceuticals Business Overview
10.9.3 Clarity Pharmaceuticals Radioimmunotherapy Introduction
10.9.4 Clarity Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024)
10.9.5 Clarity Pharmaceuticals Recent Development
10.10 Curasight
10.10.1 Curasight Company Details
10.10.2 Curasight Business Overview
10.10.3 Curasight Radioimmunotherapy Introduction
10.10.4 Curasight Revenue in Radioimmunotherapy Business (2018-2024)
10.10.5 Curasight Recent Development
10.11 Nordic Nanovector
10.11.1 Nordic Nanovector Company Details
10.11.2 Nordic Nanovector Business Overview
10.11.3 Nordic Nanovector Radioimmunotherapy Introduction
10.11.4 Nordic Nanovector Revenue in Radioimmunotherapy Business (2018-2024)
10.11.5 Nordic Nanovector Recent Development
10.12 Philogen
10.12.1 Philogen Company Details
10.12.2 Philogen Business Overview
10.12.3 Philogen Radioimmunotherapy Introduction
10.12.4 Philogen Revenue in Radioimmunotherapy Business (2018-2024)
10.12.5 Philogen Recent Development
10.13 RadioMedix
10.13.1 RadioMedix Company Details
10.13.2 RadioMedix Business Overview
10.13.3 RadioMedix Radioimmunotherapy Introduction
10.13.4 RadioMedix Revenue in Radioimmunotherapy Business (2018-2024)
10.13.5 RadioMedix Recent Development
10.14 Telix Pharmaceuticals
10.14.1 Telix Pharmaceuticals Company Details
10.14.2 Telix Pharmaceuticals Business Overview
10.14.3 Telix Pharmaceuticals Radioimmunotherapy Introduction
10.14.4 Telix Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024)
10.14.5 Telix Pharmaceuticals Recent Development
10.15 Orano Med
10.15.1 Orano Med Company Details
10.15.2 Orano Med Business Overview
10.15.3 Orano Med Radioimmunotherapy Introduction
10.15.4 Orano Med Revenue in Radioimmunotherapy Business (2018-2024)
10.15.5 Orano Med Recent Development
10.16 Actinium Pharmaceuticals
10.16.1 Actinium Pharmaceuticals Company Details
10.16.2 Actinium Pharmaceuticals Business Overview
10.16.3 Actinium Pharmaceuticals Radioimmunotherapy Introduction
10.16.4 Actinium Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024)
10.16.5 Actinium Pharmaceuticals Recent Development
10.17 Y-mAbs Therapeutics
10.17.1 Y-mAbs Therapeutics Company Details
10.17.2 Y-mAbs Therapeutics Business Overview
10.17.3 Y-mAbs Therapeutics Radioimmunotherapy Introduction
10.17.4 Y-mAbs Therapeutics Revenue in Radioimmunotherapy Business (2018-2024)
10.17.5 Y-mAbs Therapeutics Recent Development
10.18 Fusion Pharmaceuticals
10.18.1 Fusion Pharmaceuticals Company Details
10.18.2 Fusion Pharmaceuticals Business Overview
10.18.3 Fusion Pharmaceuticals Radioimmunotherapy Introduction
10.18.4 Fusion Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024)
10.18.5 Fusion Pharmaceuticals Recent Development
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.2 Data Source
12.2 Disclaimer
12.3 Author Details

List of Figure

List of Tables
Table 1. Radioimmunotherapy Market Size United States VS Global, CAGR (2018 VS 2022 VS 2029)
Table 2. Radioimmunotherapy Market Trends
Table 3. Radioimmunotherapy Market Drivers
Table 4. Radioimmunotherapy Market Challenges
Table 5. Radioimmunotherapy Market Restraints
Table 6. Global Radioimmunotherapy Market Size by Type: 2018 VS 2022 VS 2029 (US$ Million)
Table 7. United States Radioimmunotherapy Market Size by Type: 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global Radioimmunotherapy Market Size by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 9. United States Radioimmunotherapy Market Size by Application: 2018 VS 2022 VS 2029 (US$ Million)
Table 10. Global Key Companies of Radioimmunotherapy, Ranked by Revenue (2022) & (US$ Million)
Table 11. Global Radioimmunotherapy Revenue by Player, (US$ Million), 2018-2024
Table 12. Global Radioimmunotherapy Revenue Share by Player, 2018-2024
Table 13. Global Radioimmunotherapy Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Radioimmunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioimmunotherapy as of 2022)
Table 15. Global Key Players of Radioimmunotherapy, Headquarters and Area Served
Table 16. Global Key Players of Radioimmunotherapy, Product and Application
Table 17. Global Key Players of Radioimmunotherapy, Date of Enter into This Industry
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Key Players of Radioimmunotherapy in United States, Ranked by Revenue (2022) & (US$ Million)
Table 20. United States Radioimmunotherapy Revenue by Players, (US$ Million), 2021, 2022 & 2024
Table 21. United States Radioimmunotherapy Revenue Share by Players, 2021, 2022 & 2024
Table 22. Global Radioimmunotherapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 23. Global Radioimmunotherapy Market Size by Region (2018-2024) & (US$ Million)
Table 24. Global Radioimmunotherapy Market Size Forecast by Region (2024-2029) & (US$ Million)
Table 25. Americas Radioimmunotherapy Market Size by Type (2018-2024) & (US$ Million)
Table 26. Americas Radioimmunotherapy Market Size by Type (2024-2029) & (US$ Million)
Table 27. Americas Radioimmunotherapy Market Size by Application (2018-2024) & (US$ Million)
Table 28. Americas Radioimmunotherapy Market Size by Application (2024-2029) & (US$ Million)
Table 29. Americas Radioimmunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 30. Americas Radioimmunotherapy Market Size by Country (2018-2024) & (US$ Million)
Table 31. Americas Radioimmunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 32. EMEA Radioimmunotherapy Market Size by Type (2018-2024) & (US$ Million)
Table 33. EMEA Radioimmunotherapy Market Size by Type (2024-2029) & (US$ Million)
Table 34. EMEA Radioimmunotherapy Market Size by Application (2018-2024) & (US$ Million)
Table 35. EMEA Radioimmunotherapy Market Size by Application (2024-2029) & (US$ Million)
Table 36. EMEA Radioimmunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. EMEA Radioimmunotherapy Market Size by Country (2018-2024) & (US$ Million)
Table 38. EMEA Radioimmunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 39. China Radioimmunotherapy Market Size by Type (2018-2024) & (US$ Million)
Table 40. China Radioimmunotherapy Market Size by Type (2024-2029) & (US$ Million)
Table 41. China Radioimmunotherapy Market Size by Application (2018-2024) & (US$ Million)
Table 42. China Radioimmunotherapy Market Size by Application (2024-2029) & (US$ Million)
Table 43. China Radioimmunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. APAC Radioimmunotherapy Market Size by Type (2018-2024) & (US$ Million)
Table 45. APAC Radioimmunotherapy Market Size by Type (2024-2029) & (US$ Million)
Table 46. APAC Radioimmunotherapy Market Size by Application (2018-2024) & (US$ Million)
Table 47. APAC Radioimmunotherapy Market Size by Application (2024-2029) & (US$ Million)
Table 48. APAC Radioimmunotherapy Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 49. APAC Radioimmunotherapy Market Size by Region (2018-2024) & (US$ Million)
Table 50. APAC Radioimmunotherapy Market Size by Region (2024-2029) & (US$ Million)
Table 51. Bayer Company Details
Table 52. Bayer Business Overview
Table 53. Bayer Radioimmunotherapy Product
Table 54. Bayer Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 55. Bayer Recent Development
Table 56. Novartis Company Details
Table 57. Novartis Business Overview
Table 58. Novartis Radioimmunotherapy Product
Table 59. Novartis Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 60. Novartis Recent Development
Table 61. Lantheus Company Details
Table 62. Lantheus Business Overview
Table 63. Lantheus Radioimmunotherapy Product
Table 64. Lantheus Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 65. Lantheus Recent Development
Table 66. Aurobindo Pharma Company Details
Table 67. Aurobindo Pharma Business Overview
Table 68. Aurobindo Pharma Radioimmunotherapy Product
Table 69. Aurobindo Pharma Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 70. Aurobindo Pharma Recent Development
Table 71. Mundipharma Company Details
Table 72. Mundipharma Business Overview
Table 73. Mundipharma Radioimmunotherapy Product
Table 74. Mundipharma Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 75. Mundipharma Recent Development
Table 76. China Isotope & Radiation Company Details
Table 77. China Isotope & Radiation Business Overview
Table 78. China Isotope & Radiation Radioimmunotherapy Product
Table 79. China Isotope & Radiation Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 80. China Isotope & Radiation Recent Development
Table 81. Curium Pharmaceuticals Company Details
Table 82. Curium Pharmaceuticals Business Overview
Table 83. Curium Pharmaceuticals Radioimmunotherapy Product
Table 84. Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 85. Curium Pharmaceuticals Recent Development
Table 86. Gilead Sciences Company Details
Table 87. Gilead Sciences Business Overview
Table 88. Gilead Sciences Radioimmunotherapy Product
Table 89. Gilead Sciences Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 90. Gilead Sciences Recent Development
Table 91. Clarity Pharmaceuticals Company Details
Table 92. Clarity Pharmaceuticals Business Overview
Table 93. Clarity Pharmaceuticals Radioimmunotherapy Product
Table 94. Clarity Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 95. Clarity Pharmaceuticals Recent Development
Table 96. Curasight Company Details
Table 97. Curasight Business Overview
Table 98. Curasight Radioimmunotherapy Product
Table 99. Curasight Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 100. Curasight Recent Development
Table 101. Nordic Nanovector Company Details
Table 102. Nordic Nanovector Business Overview
Table 103. Nordic Nanovector Radioimmunotherapy Product
Table 104. Nordic Nanovector Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 105. Nordic Nanovector Recent Development
Table 106. Philogen Company Details
Table 107. Philogen Business Overview
Table 108. Philogen Radioimmunotherapy Product
Table 109. Philogen Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 110. Philogen Recent Development
Table 111. RadioMedix Company Details
Table 112. RadioMedix Business Overview
Table 113. RadioMedix Radioimmunotherapy Product
Table 114. RadioMedix Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 115. RadioMedix Recent Development
Table 116. Telix Pharmaceuticals Company Details
Table 117. Telix Pharmaceuticals Business Overview
Table 118. Telix Pharmaceuticals Radioimmunotherapy Product
Table 119. Telix Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 120. Telix Pharmaceuticals Recent Development
Table 121. Orano Med Company Details
Table 122. Orano Med Business Overview
Table 123. Orano Med Radioimmunotherapy Product
Table 124. Orano Med Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 125. Orano Med Recent Development
Table 126. Actinium Pharmaceuticals Company Details
Table 127. Actinium Pharmaceuticals Business Overview
Table 128. Actinium Pharmaceuticals Radioimmunotherapy Product
Table 129. Actinium Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 130. Actinium Pharmaceuticals Recent Development
Table 131. Y-mAbs Therapeutics Company Details
Table 132. Y-mAbs Therapeutics Business Overview
Table 133. Y-mAbs Therapeutics Radioimmunotherapy Product
Table 134. Y-mAbs Therapeutics Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 135. Y-mAbs Therapeutics Recent Development
Table 136. Fusion Pharmaceuticals Company Details
Table 137. Fusion Pharmaceuticals Business Overview
Table 138. Fusion Pharmaceuticals Radioimmunotherapy Product
Table 139. Fusion Pharmaceuticals Revenue in Radioimmunotherapy Business (2018-2024) & (US$ Million)
Table 140. Fusion Pharmaceuticals Recent Development
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Radioimmunotherapy Product Picture
Figure 2. Global Radioimmunotherapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 3. Global Radioimmunotherapy Market Size 2018-2029 (US$ Million)
Figure 4. United States Radioimmunotherapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 5. United States Radioimmunotherapy Market Size 2018-2029 (US$ Million)
Figure 6. United States Radioimmunotherapy Market Share in Global 2018-2029
Figure 7. Radioimmunotherapy Report Years Considered
Figure 8. Product Picture of Beta-emitting
Figure 9. Product Picture of Targeted Alpha Therapy
Figure 10. Global Radioimmunotherapy Market Share by Type in 2022 & 2029
Figure 11. Global Radioimmunotherapy Market Size by Type (2018-2029) & (US$ Million)
Figure 12. Global Radioimmunotherapy Market Share by Type (2018-2029)
Figure 13. United States Radioimmunotherapy Market Share by Type in 2022 & 2029
Figure 14. United States Radioimmunotherapy Market Size by Type (2018-2029) & (US$ Million)
Figure 15. United States Radioimmunotherapy Market Share by Type (2018-2029)
Figure 16. Product Picture of Solid Tumor
Figure 17. Product Picture of Non Hodgkin Lymphoma
Figure 18. Global Radioimmunotherapy Market Share by Application in 2022 & 2029
Figure 19. Global Radioimmunotherapy Market Size by Application (2018-2029) & (US$ Million)
Figure 20. Global Radioimmunotherapy Market Share by Application (2018-2029)
Figure 21. United States Radioimmunotherapy Market Share by Application in 2022 & 2029
Figure 22. United States Radioimmunotherapy Market Size by Application (2018-2029) & (US$ Million)
Figure 23. United States Radioimmunotherapy Market Share by Application (2018-2029)
Figure 24. The Top 5 and 10 Largest Companies of Radioimmunotherapy in the World: Market Share by Radioimmunotherapy Revenue in 2022
Figure 25. Global Radioimmunotherapy Market Size Market Share by Region: 2018 VS 2022 VS 2029
Figure 26. Global Radioimmunotherapy Market Share by Region (2018-2029)
Figure 27. Americas Radioimmunotherapy Market Size Growth Rate 2018-2029 (US$ Million)
Figure 28. Americas Radioimmunotherapy Market Share by Type (2018-2029)
Figure 29. Americas Radioimmunotherapy Market Share by Application (2018-2029)
Figure 30. United States Radioimmunotherapy Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 31. Canada Radioimmunotherapy Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 32. Mexico Radioimmunotherapy Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 33. Brazil Radioimmunotherapy Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 34. EMEA Radioimmunotherapy Market Size Growth Rate 2018-2029 (US$ Million)
Figure 35. EMEA Radioimmunotherapy Market Share by Type (2018-2029)
Figure 36. EMEA Radioimmunotherapy Market Share by Application (2018-2029)
Figure 37. Europe Radioimmunotherapy Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 38. Middle East Radioimmunotherapy Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 39. Africa Radioimmunotherapy Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 40. China Radioimmunotherapy Market Size Growth Rate 2018-2029 (US$ Million)
Figure 41. China Radioimmunotherapy Market Share by Type (2018-2029)
Figure 42. China Radioimmunotherapy Market Share by Application (2018-2029)
Figure 43. APAC Radioimmunotherapy Market Size Growth Rate 2018-2029 (US$ Million)
Figure 44. APAC Radioimmunotherapy Market Share by Type (2018-2029)
Figure 45. APAC Radioimmunotherapy Market Share by Application (2018-2029)
Figure 46. Japan Radioimmunotherapy Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 47. South Korea Radioimmunotherapy Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 48. China Taiwan Radioimmunotherapy Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 49. Southeast Asia Radioimmunotherapy Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 50. India Radioimmunotherapy Market Size Growth Rate (2018-2029) & (US$ Million)
Figure 51. Bayer Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 52. Novartis Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 53. Lantheus Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 54. Aurobindo Pharma Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 55. Mundipharma Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 56. China Isotope & Radiation Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 57. Curium Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 58. Gilead Sciences Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 59. Clarity Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 60. Curasight Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 61. Nordic Nanovector Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 62. Philogen Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 63. RadioMedix Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 64. Telix Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 65. Orano Med Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 66. Actinium Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 67. Y-mAbs Therapeutics Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 68. Fusion Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2018-2024)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed